ERBB2 and gastric cancer: Importantly, survival analysis showed that co‐overexpression group (PGAP3‐high/ERBB2‐high) contributed to the worst prognosis in patients with GC (24.8%), indicated an important and synergistic effect of PGAP3 and ERBB2 on the prognosis of GC.